Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 17, 2025Sensors & DiagnosticsOpen Access

CRISPR-Based Diagnostics for Circulating Cell-Free DNA: A Paradigm Shift in Precision Oncology

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSahil SethKPK. Sudhakara Prasad

Discussion

Loading...

Member takes

Overview

Crispr-based diagnostics improves detection of cancer using circulating cell-free DNA, suggesting enhanced precision oncology benefits.

Key Points

  • Circulating cell-free DNA (cfDNA) diagnostics enhances cancer detection and monitoring, improving patient outcomes.
  • The method improves diagnosis accuracy and treatment response monitoring, proving crucial for precision oncology.
  • CRISPR-based diagnostics allow real-time tracking of cancer via cfDNA, demonstrating significant advancements in non-invasive testing.
  • This approach may facilitate earlier cancer detection and personalized treatment strategies, aiming for better survival rates.

Cite This Study

Seth et al. (2025) studied this question.

synapsesocial.com/papers/68c2368eb210217d64774d22https://doi.org/10.1039/d5sd00083a
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Circulating tumor cells and tumor-derived cell-free DNA in cancer management: Clinical evidence, limitations, and future directions2026
  2. 2Harnessing viral footprints in circulating free <scp>DNA</scp> (<scp>cfDNA</scp>) for early cancer detection: A focus on liquid‐biopsy‐based screening2025
  3. 3CRISPR-Powered Liquid Biopsies in Cancer Diagnostics2025
  4. 4Emerging Technologies for Detection of Cell-Free Tumor DNA and RNA in Serum: Towards Early Cancer Detection and Monitoring2025
  5. 5Multi-Biofluid Approaches for cftDNA and cftRNA Biomarker Detection: Advances in Early Cancer Detection and Monitoring2025